# Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

> **NCT02772614** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 4 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** BIA 3-202 (200 mg)

## Key facts

- **NCT ID:** NCT02772614
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772614, "Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02772614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*